Koers Reviva Pharmaceuticals Holdings, Inc. Nasdaq
Aandelen
TZAC
US76152G1004
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 85,43 mln. 80,07 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -37 mln. -34,68 mln. | Nettowinst (verlies) 2025 * | -43 mln. -40,3 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 39,9 mln. 37,4 mln. | Nettoliquiditeiten 2025 * | 31,9 mln. 29,9 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,46
x | K/w-verhouding 2025 * |
-2,32
x | Werknemers | 15 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 82,23% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 59 | 11-12-20 | |
Narayan Prabhu
DFI | Director of Finance/CFO | 53 | 14-12-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 69 | 14-12-20 | |
Les Funtleyder
BRD | Director/Board Member | 55 | 14-12-20 |
Founder | 59 | 11-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,19 mld. | |
+10,92% | 42,24 mld. | |
+44,30% | 40,15 mld. | |
-6,20% | 28,31 mld. | |
+5,23% | 24,63 mld. | |
-24,79% | 18,2 mld. | |
+26,69% | 12,01 mld. | |
-3,13% | 11,76 mld. | |
+6,57% | 10,4 mld. |